Zuranolone (ZURZUVAE)
Postpartum Depression
MarketedCo-promotion
Key Facts
About Neurocrine Biosciences
Neurocrine Biosciences has successfully transitioned from a discovery-focused entity to a fully integrated commercial leader in neuroscience. Its mission is to relieve suffering through brave science, exemplified by the blockbuster success of INGREZZA for tardive dyskinesia and a growing portfolio in movement disorders and endocrinology. The company's strategy leverages deep neurobiological expertise to advance a diversified pipeline, pursue strategic collaborations, and expand the labels of its commercial assets to drive sustainable growth.
View full company profileTherapeutic Areas
Other Postpartum Depression Drugs
| Drug | Company | Phase |
|---|---|---|
| ZURZUVAE (zuranolone) | Sage Therapeutics | Approved |
| BRII-296 | Brii Biosciences | Phase 1 |
| Postpartum Depression Program | Biogen | Not Specified |